Влияние длительного применения тиотропия на функцию легких у больных хронической обструктивной болезнью легких: исследование UPLIFT

1. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.

2. Tashkin D.P., Cooper C.B. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125: 249–251.

3. van Noord J. A., Aumann J. L., Janssens E. et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. 2005; 26: 214–222.

4. Rabe K.F., Timmer W., Sagriotis A., Viel K. Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. Eur. Respir. J. 2005; 26 (suppl. 49): 14s.

5. Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1977; 1: 1645–1648.

6. Tashkin D.P. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding. Am. J. Med. 2006; 119 (10, suppl.1): 63–72.

7. Anzueto A. Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions. Am. J. Med. 2006; 119 (10, suppl. 1): 46–53.

8. Vestbo J., TORCH Study Group. The TORCH (towards a revolution in COPD health) survival study protocol. Eur. Respir. J. 2004; 24: 206–210.

9. Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–789.

10. Celli B.R., Thomas N.E., Anderson J.A. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178: 332–338.

11. Rabe K. Treating COPD – the TORCH trial, P value and the Dodo. N. Engl. J. Med. 2007; 356: 851–854.

12. Suissa S., Ernst P., Vandemheen K.L., Aaron S.D. Methodological issues in therapeutic trials of COPD. Eur. Respir. J. 2008; 31: 927–933.

13. Hodder R., Kesten S., Menjoge S., Viel K. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Int. J. Chron. Obstruct. Pulm. Dis. 2007; 2: 157–167.

14. Decramer M., Celli B., Tashkin D.P. et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. J. COPD 2004; 1: 303–312.

15. Casaburi R., Mahler D.A., Jones P.A. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217–224.

16. Vincken W., van Noord J.A., Greefhorst A.P.M. et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209–216.

17. Brusasco V., Hodder R., Miravitlles M. et al. Health out comes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404.

18. O'Donnell D., Fluge T., Gerken F. et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in patients with COPD. Eur. Respir. J. 2004; 23: 832–840.

19. Dusser D., Bravo M-L., Iacono P. on behalf of the MISTRAL study group. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 2006; 27: 547–555.

20. Anzueto A., Menjoge S.S., Kesten S. Changes in FEV I overtime in one year clinical trials of tiotropium in COPD. Am. J. Respir. Crit. Care Med. 2001; 163: A280.

21. Anzueto A. Disease modification in chronic obstructive pulmonary disease. Clin. Chest Med. 2007; 28: 609–616.

22. Tashkin D.P., Celli B., Decramer M. D. et al. Bronchodilator responsiveness in patients with COPD. Eur. Respir. J. 2008; 31: 742–750.

23. Tashkin D.P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543–1554.